FDA Approves Combo for Indolent Non-Hodgkin Lymphomas FDA Approves Combo for Indolent Non-Hodgkin Lymphomas

Lenalidomide may now be used in combination with rituximab for previously treated follicular lymphoma and previously treated marginal zone lymphoma.FDA Approvals

Source: Medscape Medical News Headlines - May 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news